Eli Lilly: Three Products, One Molecule, Total Dominance Lilly's GLP-1 franchise is built on tirzepatide, a dual GLP-1/GIP receptor agonist, sold as Mounjaro for type 2 diabetes and Zepbound for obesity
Spending on glucagonlike peptide1 receptor agonists, or GLP1s, in the United States increased over 500% from $13.7 billion in 2018 to $71.7 billion in 2023, according to the Journal of the American Heart Association, Although these medications were initially developed to treat Type 2 diabetes, newer indications now include weight management
While the occurrence is low, this highlights the importance of monitoring and early intervention, especially in individuals with pre-existing conditions that may predispose them to pancreatitis, such as gallstones, high triglycerides, chronic alcohol use and obesity
A comprehensive analysis of 43,365 individuals from two US healthcare databases indicated that GLP-1 RAs do not elevate the risk of pulmonary aspiration during upper gastrointestinal endoscopy in patients with T2DM when compared to SGLT-2 inhibitors, yielding a pooled risk ratio of 0.98 (95% CI, 0.73 to 1.31) among GLP-1 RA users